- China Overcapacity Worsening, EU Chamber Warns
- Investing in Good Karma – and Making a Profit
- China Unveils Carbon Target Ahead of Copenhagen
- Wal-Mart Price Pressure Hurts China Workers: Report
- UK Banks Must Disclose Top Pay: Review
- Black Friday to Avoid Red Ink; Greenback Gets the Blues
- Bankruptcies Jump, Hitting Highest Level in Four Years
- Steepest Black Friday Discounts, Revealed
- Where Do Pardoned Turkeys Go?
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
MOST SHARED
- The Executive Job Search
- Chinese Overcapacity is Worsening, EU Chamber Warns
- Where Do Pardoned Turkeys Go?
- US Mint to Suspend American Eagle Gold 1-Ounce Coins
- Salvation Army's Kettles Now Credit Card-Ready
- Activision Prepares to Double Dip on ‘Modern Warfare 2’
- Trader Talk
- Topless Business Is Taking Off
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
Text Size 
Bristol-Myers Squibb said on Sunday it plans to split off its 83 percent stake in Mead Johnson Nutrition Company in a deal that lets Bristol shareholders exchange their shares for Mead Johnson common stock.
Under terms of the offer, for each $1.00 of Bristol-Myers common stock accepted in the exchange offer, the tendering shareholder will receive about $1.11 of Mead Johnson common stock.
The exchange ratio will be determined by a 10 percent discount to the average of the daily volume-weighted average price of Bristol-Myers Squibb [BMY
Loading...
()
] common stock and Mead Johnson [MJN
Loading...
()
] common shares over a three-day period expected to be Dec. 8, 9, and 10, 2009.
Based on the 170 million shares of Mead Johnson owned by Bristol, and Mead Johnson's closing stock price on Friday, Nov. 13, of $45.25 on the New York Stock Exchange, the market cap of the stake that is being spun off would be about $7.69 billion.
But the proceeds will depend on how many shares are tendered. Bristol said the exchange "is generally expected" to be tax-free to shareholders, and is expected to be accretive to earnings in 2010. The company declined to comment on how it would use its proceeds.
"Now is the right time to move forward with a split-off, given the excellent performance of Mead Johnson since the IPO earlier this year and our confidence in the current and future performance of our biopharmaceuticals business," Bristol Chief Executive James M. Cornelius said in a statement.
Bristol took Mead Johnson, which makes infant formula, public in February, as part of its effort to focus on biopharmaceuticals.
Mead raised $720 million in gross proceeds from its initial public offering.
"With a successful execution of this split-off, we fully consider ourselves a BioPharma company," he said.
The completion of the exchange offer is subject to certain conditions, including that at least 144.5 million shares of Mead Johnson common stock will be distributed in the exchange.
- For nearly three decades, these on-call experts have been dishing advice on how to – and not to – cook turkey.
- Eric Schmidt pledges to create a virtual copy of the Iraq National Museum at Google’s expense.
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- More shoppers than ever plan to comparison-shop this season. Who will benefit?
- It may be the most unusual guide to business you'll read.
- How can you get out of debt and back on the road to recovery? Follow these ten steps.
Data is a real-time snapshot *Data is delayed at least 15 minutes